JPMorgan Chase & Co. lifted its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 144.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 140,559 shares of the company's stock after buying an additional 83,048 shares during the period. JPMorgan Chase & Co. owned about 0.21% of Amylyx Pharmaceuticals worth $455,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of AMLX. China Universal Asset Management Co. Ltd. raised its stake in shares of Amylyx Pharmaceuticals by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company's stock worth $42,000 after acquiring an additional 5,104 shares in the last quarter. Algert Global LLC bought a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter valued at $47,000. Hsbc Holdings PLC raised its position in Amylyx Pharmaceuticals by 57.9% in the 2nd quarter. Hsbc Holdings PLC now owns 76,261 shares of the company's stock worth $150,000 after purchasing an additional 27,954 shares during the period. Barclays PLC lifted its stake in Amylyx Pharmaceuticals by 91.1% in the third quarter. Barclays PLC now owns 84,572 shares of the company's stock worth $274,000 after purchasing an additional 40,319 shares during the last quarter. Finally, Maven Securities LTD lifted its stake in Amylyx Pharmaceuticals by 300.0% in the second quarter. Maven Securities LTD now owns 100,000 shares of the company's stock worth $190,000 after purchasing an additional 75,000 shares during the last quarter. Institutional investors own 95.84% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on the company. Baird R W raised Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 18th. Bank of America upgraded Amylyx Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price target for the stock from $4.20 to $10.00 in a research report on Wednesday, October 23rd. HC Wainwright reiterated a "buy" rating and issued a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Thursday, December 5th. Leerink Partners set a $4.00 target price on shares of Amylyx Pharmaceuticals and gave the stock a "market perform" rating in a report on Friday, October 18th. Finally, Robert W. Baird raised shares of Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and lifted their target price for the stock from $3.00 to $11.00 in a research note on Monday, November 18th. Five research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.33.
Check Out Our Latest Stock Analysis on AMLX
Amylyx Pharmaceuticals Stock Up 4.0 %
Shares of AMLX traded up $0.14 during mid-day trading on Friday, hitting $3.65. 1,391,760 shares of the company's stock traded hands, compared to its average volume of 873,081. The firm has a market capitalization of $250.21 million, a P/E ratio of -0.96 and a beta of -0.53. The business's 50-day moving average price is $4.15 and its 200-day moving average price is $3.62. Amylyx Pharmaceuticals, Inc. has a 1 year low of $1.58 and a 1 year high of $19.95.
Insider Buying and Selling at Amylyx Pharmaceuticals
In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 7,471 shares of the firm's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $4.04, for a total value of $30,182.84. Following the completion of the sale, the chief executive officer now directly owns 3,176,788 shares in the company, valued at $12,834,223.52. This trade represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 11.70% of the company's stock.
About Amylyx Pharmaceuticals
(
Free Report)
Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
Further Reading
Before you consider Amylyx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.
While Amylyx Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
